New viral vaccines - PubMed

Review

New viral vaccines

Ann M Arvin et al. Virology. 2006.

Free article

Abstract

Vaccination is the most effective medical intervention against diseases caused by human viral pathogens. Viral vaccines prevent or modify the severity of illness in the individual and interrupt or reduce the transmission of the pathogens to other susceptible people. Through these mechanisms, vaccines against smallpox, polio, measles and hepatitis B have had an enormous impact on world health over the last 50 years. Advances in basic virology and understanding of human immunity promise more progress in the control of human viral diseases as the 21st century begins. Some important targets, including human immunodeficiency virus, respiratory syncytial virus and hepatitis C virus present challenges that require more basic research. The purpose of this review is to highlight four new viral vaccines that have recently, or will soon demonstrate the effective translation of basic investigations into clinical benefits for disease control in healthy and high-risk populations. These vaccines include the live attenuated vaccines against the RNA viruses, rotavirus and influenza A and B, and vaccines against human papilloma virus and varicella-zoster virus, which are DNA viruses that cause morbidity and mortality through their capacity to establish persistent infection. Although only the influenza vaccine has been licensed in the United States, these other new tools for disease prevention are likely to be introduced within the next few years, with profound effects on the diseases that they cause. Hence, as Virology celebrates its 50th anniversary, it is appropriate to examine these examples of recent advances in viral vaccines.

Similar articles

• Vaccines in the prevention of viral pneumonia.

  Betts RF. Betts RF. Semin Respir Infect. 1995 Dec;10(4):282-7. Semin Respir Infect. 1995. PMID: 8668856 Review.

• New opportunities for development of safe, effective live virus vaccines.

  Chanock RM. Chanock RM. Yale J Biol Med. 1982 May-Aug;55(3-4):361-7. Yale J Biol Med. 1982. PMID: 6295011 Free PMC article.

• Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations.

  Wu JJ, Huang DB, Pang KR, Tyring SK. Wu JJ, et al. J Am Acad Dermatol. 2004 Apr;50(4):495-528; quiz 529-32. doi: 10.1016/j.jaad.2003.12.003. J Am Acad Dermatol. 2004. PMID: 15034501 Review.

• Influenza: evolving strategies in treatment and prevention.

  Lynch JP 3rd, Walsh EE. Lynch JP 3rd, et al. Semin Respir Crit Care Med. 2007 Apr;28(2):144-58. doi: 10.1055/s-2007-976487. Semin Respir Crit Care Med. 2007. PMID: 17458769 Review.

• Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.

  Patel MM, Parashar UD. Patel MM, et al. J Infect Dis. 2009 Nov 1;200 Suppl 1:S291-9. doi: 10.1086/605059. J Infect Dis. 2009. PMID: 19817612 Review.

Cited by

• Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation.

  Renukaradhya GJ, Narasimhan B, Mallapragada SK. Renukaradhya GJ, et al. J Control Release. 2015 Dec 10;219:622-631. doi: 10.1016/j.jconrel.2015.09.047. Epub 2015 Sep 26. J Control Release. 2015. PMID: 26410807 Free PMC article. Review.

• A universal design of restructured dimer antigens: Development of a superior vaccine against the paramyxovirus in transgenic rice.

  Ma F, Xu Q, Wang A, Yang D, Li Q, Guo J, Zhang L, Ou J, Li R, Yin H, Li K, Wang L, Wang Y, Zhao X, Niu X, Zhang S, Li X, Chai S, Zhang E, Rao Z, Zhang G. Ma F, et al. Proc Natl Acad Sci U S A. 2024 Jan 23;121(4):e2305745121. doi: 10.1073/pnas.2305745121. Epub 2024 Jan 18. Proc Natl Acad Sci U S A. 2024. PMID: 38236731 Free PMC article.

• A new polymorphism in the GRP78 is not associated with HBV invasion.

  Zhu X, Wang Y, Tao T, Li DP, Lan FF, Zhu W, Xie D, Kung HF. Zhu X, et al. World J Gastroenterol. 2009 Oct 21;15(39):4958-61. doi: 10.3748/wjg.15.4958. World J Gastroenterol. 2009. PMID: 19842229 Free PMC article.

• Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.

  Chavda VP, Yao Q, Vora LK, Apostolopoulos V, Patel CA, Bezbaruah R, Patel AB, Chen ZS. Chavda VP, et al. Front Immunol. 2022 Oct 3;13:961198. doi: 10.3389/fimmu.2022.961198. eCollection 2022. Front Immunol. 2022. PMID: 36263030 Free PMC article. Review.

• SARS-CoV-2 variants and vulnerability at the global level.

  Chavda VP, Patel AB, Vaghasiya DD. Chavda VP, et al. J Med Virol. 2022 Jul;94(7):2986-3005. doi: 10.1002/jmv.27717. Epub 2022 Apr 5. J Med Virol. 2022. PMID: 35277864 Free PMC article. Review.

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database